These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Hypotensive effect of carteolol in patients with essential hypertension].
    Author: Beythien RD.
    Journal: Arzneimittelforschung; 1983; 33(2a):330-3. PubMed ID: 6682325.
    Abstract:
    The ability of 5-(3-tert-butylamino-2-hydroxy-propoxy)-3, 4-dihydro-2(1H)-quinolinone hydrochloride (carteolol hydrochloride, Endak, Endak mite) to lower the blood pressure was tested in an open clinical study on 66 patients with I-III degree essential hypertension. The results for 49 of the 66 patients were interpretable after 4 weeks, and for 39 of them after 12 weeks. Even with a single dose of 5 mg/day 33 of the patients had normalized blood pressures after 4 weeks (systolic less than 160, diastolic less than 95 mmHg); in a further 6 patients 10 mg led to normal blood pressure. For 10 patients, 4 weeks on 10 mg did not lead to an adequate response. After 12 weeks, of the 39 cases that could be checked, 19 were normalized on 5 mg, 2 on 10 mg and another 4 on 15 mg. Even 15 mg was insufficient to reduce the blood pressure of 14 of the patients adequately. Carteolol, at doses of 5-15 mg/day, caused a therapeutically acceptable lowering of the blood pressure in 60-80% of cases of essential hypertension of all 3 degrees of severity. Only 5 of the patients suffered from side-effects, none of which caused the treatment to be abandoned. A bradycardia was never observed during up to 12 weeks of continuous treatment. Tachycardias reverted to sinus rhythms of normal frequency. Blood pressure measurement by the patients themselves proved successful.
    [Abstract] [Full Text] [Related] [New Search]